Loading...
Please wait, while we are loading the content...
and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer
| Content Provider | CiteSeerX |
|---|---|
| Author | Ruiz, Amparo Gonzalez, Sonia Alba, Emilio Almenar, Sergio Rodríguez-Lescure, Álvaro Martín, Miguel Seguí, Miguel Angel Mel, Jose Ramón Alvarez, Isabel Sánchez-Rovira, Pedro Ramos, Manuel Baena, José Manuel Manuel, Jose Alava, Enrique De Munárriz, Blanca Lluch, Ana Luis, José Puche, García García, López Adrover, Encarna Marco, Gracia Antonio, José Antón, Antonio Calvo, Lourdes Vera, Francisco González-Palacios, O. Álvarez, José Valero De, Spain E. Ruiz-Borrego, Manuel Fern, Jesús Rodríguez, César A. Palacios, José Pelegrí, Amadeu López-Vega, José Manuel Crespo, Carmen Ar, Enrique Plazaola, Arrate Mayordomo, José Ignacio Modolell, Alfonso Guitián, María Dolores |
| Abstract | On behalf of the GEICAM 9906 Study Investigators Background Taxanes are among the most active drugs for the treatment of metastatic breast cancer, and, as a conse-quence, they have also been studied in the adjuvant setting. Methods After breast cancer surgery, women with lymph node – positive disease were randomly assigned to treat-ment with fluorouracil, epirubicin, and cyclophosphamide (FEC) or with FEC followed by weekly paclitaxel |
| File Format | |
| Access Restriction | Open |
| Subject Keyword | Cyclophosphamide Alone Adjuvant Setting Weekly Paclitaxel Study Investigator Background Taxanes Metastatic Breast Cancer Early Breast Cancer Active Drug Lymph Node Positive Disease Breast Cancer Surgery |
| Content Type | Text |